Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020
04 Maio 2020 - 5:05PM
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage
pharmaceutical company focused on developing innovative and
differentiated prescription therapeutics for the treatment of
debilitating skin diseases, today announced that it will report its
first quarter 2020 financial results after the close of the U.S.
financial markets on Wednesday, May 13, 2020. Brickell’s management
will host a conference call at 4:30 p.m. ET to discuss the
financial results and recent corporate highlights.
The dial-in number for the conference call is
1-855-327-6837 for domestic participants and 1-631-891-4304 for
international participants, with Conference ID #10009475. A
live webcast of the conference call can be accessed through the
“Investors” tab on the Brickell Biotech website at
http://www.brickellbio.com/. A replay will be available on
this website shortly after conclusion of the event for 90 days.
About Brickell
Brickell Biotech, Inc. is a clinical-stage
pharmaceutical company focused on developing innovative and
differentiated prescription therapeutics for the treatment of
debilitating skin diseases. Brickell’s pipeline consists of
potential novel therapeutics for hyperhidrosis and other prevalent
dermatological conditions. Brickell’s executive management team and
board of directors bring extensive experience in product
development and global commercialization, having served in
leadership roles at large global pharmaceutical companies and
biotechs that have developed and/or launched successful products,
including several that were first-in-class and/or achieved iconic
status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and
Juvederm®. Brickell’s strategy is to leverage this experience to
in-license, acquire, develop and commercialize innovative products
that Brickell believes can be successful in the currently
underserved dermatology global marketplace. For more information,
visit http://www.brickellbio.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements made in this press release relating to future
financial, business and/or research and clinical performance,
conditions, plans, prospects, trends, or strategies and other such
matters, including without limitation, the anticipated timing,
scope, design and/or results of future clinical trials and
prospects for commercializing any of Brickell’s product candidates,
including in Japan, the United States or any other country, are
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. In addition, when or if
used in this press release, the words “may,” “could,” “should,”
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,”
“predict” and similar expressions and their variants, as they
relate to Brickell, may identify forward-looking statements.
Brickell cautions that these forward-looking statements are subject
to numerous assumptions, risks, and uncertainties, which change
over time, often quickly and in unanticipated ways. Important
factors that may cause actual results to differ materially from the
results discussed in the forward-looking statements or historical
experience include risks and uncertainties, including without
limitation, ability to obtain adequate financing to advance product
development, potential delays for any reason in product
development, regulatory changes, unanticipated demands on cash
resources, any disruption to our business caused by the current
COVID-19 pandemic, and risks associated with developing, and
obtaining regulatory approval for and commercializing novel
therapeutics.
Further information on the factors and risks that could cause
actual results to differ from any forward-looking statements are
contained in Brickell’s filings with the United States Securities
and Exchange Commission (SEC), which are available
at http://www.sec.gov (or at http://www.brickellbio.com).
The forward-looking statements represent the estimates of Brickell
as of the date hereof only, and Brickell specifically disclaims any
duty or obligation to update forward-looking statements.
Brickell Investor Contact:Patti
BankManaging Director, WestwickeIR@brickellbio.com
Brickell Biotech (NASDAQ:BBI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Brickell Biotech (NASDAQ:BBI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024